{"title":"沙比利/缬沙坦钠对急性心肌梗死PCI术后心力衰竭患者心功能及心室重构的影响。","authors":"Yawei Jia, Cheng Zhao, Kun Cui, Yunjin Zhang, Guangdong Wang, Qiong Yao, Yuanzheng Zhang","doi":"10.62347/UKIS9778","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effect of sacubitril/valsartan sodium on patients with heart failure following percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI), with a focus on changes in cardiac function and vascular endothelial function.</p><p><strong>Methods: </strong>This retrospective study analyzed data from 108 patients diagnosed with AMI and heart failure after PCI between June 2023 and June 2024. Patients were allocated into two groups based on the treatment regimen. The control group received standard therapy supplemented with valsartan. The study group received sacubitril/valsartan sodium in place of valsartan, in addition to the same standard regimen. Key outcome measures included markers of myocardial injury [cardiac troponin I (cTnI), high-sensitivity C-reactive protein (hs-CRP), and N-terminal pro-brain natriuretic peptide (NT-proBNP)], echocardiographic parameters, indices of cardiac function and ventricular remodeling, six-minute walk distance (6MWD), Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, major adverse cardiovascular events (MACEs), and incidence of adverse reactions.</p><p><strong>Results: </strong>Baseline characteristics were comparable between the two groups. Post-treatment, the study group demonstrated a significantly higher clinical efficacy (P < 0.05). Myocardial injury markers decreased more markedly, and improvements in cardiac function were significantly greater in the study group compared to the control group (P < 0.05). Although the study group exhibited lower incidences of MACEs and adverse reactions, the differences were not statistically significant.</p><p><strong>Conclusion: </strong>Sacubitril/valsartan sodium can significantly improve cardiac function and vascular endothelial function and attenuate ventricular remodeling in patients with heart failure after PCI for AMI. The treatment is well tolerated and demonstrates a favorable safety profile.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 6","pages":"4713-4722"},"PeriodicalIF":1.7000,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261145/pdf/","citationCount":"0","resultStr":"{\"title\":\"The effect of sacubitril/valsartan sodium on cardiac function and ventricular remodeling in patients with heart failure after PCI for acute myocardial infarction.\",\"authors\":\"Yawei Jia, Cheng Zhao, Kun Cui, Yunjin Zhang, Guangdong Wang, Qiong Yao, Yuanzheng Zhang\",\"doi\":\"10.62347/UKIS9778\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To evaluate the effect of sacubitril/valsartan sodium on patients with heart failure following percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI), with a focus on changes in cardiac function and vascular endothelial function.</p><p><strong>Methods: </strong>This retrospective study analyzed data from 108 patients diagnosed with AMI and heart failure after PCI between June 2023 and June 2024. Patients were allocated into two groups based on the treatment regimen. The control group received standard therapy supplemented with valsartan. The study group received sacubitril/valsartan sodium in place of valsartan, in addition to the same standard regimen. Key outcome measures included markers of myocardial injury [cardiac troponin I (cTnI), high-sensitivity C-reactive protein (hs-CRP), and N-terminal pro-brain natriuretic peptide (NT-proBNP)], echocardiographic parameters, indices of cardiac function and ventricular remodeling, six-minute walk distance (6MWD), Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, major adverse cardiovascular events (MACEs), and incidence of adverse reactions.</p><p><strong>Results: </strong>Baseline characteristics were comparable between the two groups. Post-treatment, the study group demonstrated a significantly higher clinical efficacy (P < 0.05). Myocardial injury markers decreased more markedly, and improvements in cardiac function were significantly greater in the study group compared to the control group (P < 0.05). Although the study group exhibited lower incidences of MACEs and adverse reactions, the differences were not statistically significant.</p><p><strong>Conclusion: </strong>Sacubitril/valsartan sodium can significantly improve cardiac function and vascular endothelial function and attenuate ventricular remodeling in patients with heart failure after PCI for AMI. The treatment is well tolerated and demonstrates a favorable safety profile.</p>\",\"PeriodicalId\":7731,\"journal\":{\"name\":\"American journal of translational research\",\"volume\":\"17 6\",\"pages\":\"4713-4722\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-06-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261145/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of translational research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.62347/UKIS9778\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of translational research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/UKIS9778","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
The effect of sacubitril/valsartan sodium on cardiac function and ventricular remodeling in patients with heart failure after PCI for acute myocardial infarction.
Objective: To evaluate the effect of sacubitril/valsartan sodium on patients with heart failure following percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI), with a focus on changes in cardiac function and vascular endothelial function.
Methods: This retrospective study analyzed data from 108 patients diagnosed with AMI and heart failure after PCI between June 2023 and June 2024. Patients were allocated into two groups based on the treatment regimen. The control group received standard therapy supplemented with valsartan. The study group received sacubitril/valsartan sodium in place of valsartan, in addition to the same standard regimen. Key outcome measures included markers of myocardial injury [cardiac troponin I (cTnI), high-sensitivity C-reactive protein (hs-CRP), and N-terminal pro-brain natriuretic peptide (NT-proBNP)], echocardiographic parameters, indices of cardiac function and ventricular remodeling, six-minute walk distance (6MWD), Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, major adverse cardiovascular events (MACEs), and incidence of adverse reactions.
Results: Baseline characteristics were comparable between the two groups. Post-treatment, the study group demonstrated a significantly higher clinical efficacy (P < 0.05). Myocardial injury markers decreased more markedly, and improvements in cardiac function were significantly greater in the study group compared to the control group (P < 0.05). Although the study group exhibited lower incidences of MACEs and adverse reactions, the differences were not statistically significant.
Conclusion: Sacubitril/valsartan sodium can significantly improve cardiac function and vascular endothelial function and attenuate ventricular remodeling in patients with heart failure after PCI for AMI. The treatment is well tolerated and demonstrates a favorable safety profile.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
